• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serum inflammatory factors are positively correlated with the production of specific antibodies in coronavirus disease 2019 patients.

作者信息

Zheng Meijuan, Gao Yong, Liu Siyu, Sun Dandan, Yang Fan, Zong Lu, Zhang Min, Tian Zhigang, Xu Yuanhong, Sun Haoyu

机构信息

Department of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Department of Clinical Laboratory, Fuyang Second People's Hospital, Fuyang, Anhui, China.

出版信息

Cell Mol Immunol. 2020 Nov;17(11):1180-1182. doi: 10.1038/s41423-020-00551-1. Epub 2020 Sep 22.

DOI:10.1038/s41423-020-00551-1
PMID:32963357
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7506822/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa7/7506822/4038d7b1e4c4/41423_2020_551_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa7/7506822/4038d7b1e4c4/41423_2020_551_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa7/7506822/4038d7b1e4c4/41423_2020_551_Fig1_HTML.jpg

相似文献

1
Serum inflammatory factors are positively correlated with the production of specific antibodies in coronavirus disease 2019 patients.血清炎症因子与2019冠状病毒病患者特异性抗体的产生呈正相关。
Cell Mol Immunol. 2020 Nov;17(11):1180-1182. doi: 10.1038/s41423-020-00551-1. Epub 2020 Sep 22.
2
Protective humoral immunity in SARS-CoV-2 infected pediatric patients.新冠病毒感染的儿科患者中的保护性体液免疫
Cell Mol Immunol. 2020 Jul;17(7):768-770. doi: 10.1038/s41423-020-0438-3. Epub 2020 May 7.
3
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.COVID-19 患者血清和唾液中针对 SARS-CoV-2 刺突抗原的抗体反应持续存在。
Sci Immunol. 2020 Oct 8;5(52). doi: 10.1126/sciimmunol.abe5511.
4
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.患者康复前伴随免疫反应的广度：非重症COVID-19病例报告
Nat Med. 2020 Apr;26(4):453-455. doi: 10.1038/s41591-020-0819-2.
5
Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.新型冠状病毒血清中和抗体的持续时间：严重急性呼吸综合征冠状病毒感染的经验教训。
J Microbiol Immunol Infect. 2020 Oct;53(5):821-822. doi: 10.1016/j.jmii.2020.03.015. Epub 2020 Mar 25.
6
Double-Edged Spike-Are SARS-CoV-2 Serologic Tests Safe Right Now?双刃剑——目前新冠病毒血清学检测安全吗？
Lab Med. 2020 May 6;51(3):236-238. doi: 10.1093/labmed/lmaa025.
7
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.新型冠状病毒感染恢复期个体中 SARS-CoV-2 特异性体液和细胞免疫的检测。
Immunity. 2020 Jun 16;52(6):971-977.e3. doi: 10.1016/j.immuni.2020.04.023. Epub 2020 May 3.
8
Serum IgA, IgM, and IgG responses in COVID-19.新冠病毒肺炎中的血清IgA、IgM和IgG反应。
Cell Mol Immunol. 2020 Jul;17(7):773-775. doi: 10.1038/s41423-020-0474-z. Epub 2020 May 28.
9
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.与 SARS-CoV-2 存活相关的早期血清学特征。
Immunity. 2020 Sep 15;53(3):524-532.e4. doi: 10.1016/j.immuni.2020.07.020. Epub 2020 Jul 30.
10
Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies.新冠病毒核糖核酸（RNA）复发的康复新冠患者体内抗受体结合域（RBD）抗体水平较低。
Cell Mol Immunol. 2020 Oct;17(10):1098-1100. doi: 10.1038/s41423-020-00528-0. Epub 2020 Sep 16.

引用本文的文献

1
Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents.SARS-CoV-2 奥密克戎变异株感染康复者的固有免疫印记。
Signal Transduct Target Ther. 2022 Nov 16;7(1):377. doi: 10.1038/s41392-022-01237-y.
2
Plasticity of natural killer cells in pregnant patients infected with SARS-CoV-2 and their neonates during childbirth.在分娩期间感染 SARS-CoV-2 的孕妇及其新生儿的自然杀伤细胞的可塑性。
Front Immunol. 2022 Jul 15;13:893450. doi: 10.3389/fimmu.2022.893450. eCollection 2022.
3
Considerations for Novel COVID-19 Mucosal Vaccine Development.

本文引用的文献

1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.致病性T细胞和炎性单核细胞在重症COVID-19患者中引发炎症风暴。
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
A dynamic COVID-19 immune signature includes associations with poor prognosis.一个动态的 COVID-19 免疫特征包括与预后不良的关联。
Nat Med. 2020 Oct;26(10):1623-1635. doi: 10.1038/s41591-020-1038-6. Epub 2020 Aug 17.
3
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
新型新冠病毒黏膜疫苗研发的考量因素
Vaccines (Basel). 2022 Jul 23;10(8):1173. doi: 10.3390/vaccines10081173.
4
Landscape of Peripheral Blood Mononuclear Cells and Soluble Factors in Severe COVID-19 Patients With Pulmonary Fibrosis Development.严重 COVID-19 患者发生肺纤维化时外周血单个核细胞及可溶性因子的变化。
Front Immunol. 2022 Apr 26;13:831194. doi: 10.3389/fimmu.2022.831194. eCollection 2022.
5
Asymptomatic SARS-CoV-2 infection in an unvaccinated 97-year-old woman: A case report.一名97岁未接种疫苗女性的无症状新冠病毒感染：病例报告
Biomed Rep. 2021 Dec;15(6):107. doi: 10.3892/br.2021.1483. Epub 2021 Oct 28.
6
Modulation of Host Immune Response Is an Alternative Strategy to Combat SARS-CoV-2 Pathogenesis.调控宿主免疫应答是对抗 SARS-CoV-2 发病机制的一种替代策略。
Front Immunol. 2021 Jul 8;12:660632. doi: 10.3389/fimmu.2021.660632. eCollection 2021.
7
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.无论住院时新冠病情严重程度如何，新冠病毒2型特异性体液免疫和细胞免疫均可持续9个月。
Clin Transl Immunology. 2021 Jul 5;10(7):e1306. doi: 10.1002/cti2.1306. eCollection 2021.
8
Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease.酶动力学和结合研究确定了免疫调节酶ScpA（一种C5a失活细菌蛋白酶）特异性的决定因素。
Comput Struct Biotechnol J. 2021;19:2356-2365. doi: 10.1016/j.csbj.2021.04.024. Epub 2021 Apr 17.
9
Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity.了解新型冠状病毒2型临床免疫病理学和新冠肺炎疾病严重程度的路线图
Pathogens. 2020 Dec 23;10(1):5. doi: 10.3390/pathogens10010005.
COVID-19 炎症与 C5a-C5aR1 轴的激活有关。
Nature. 2020 Dec;588(7836):146-150. doi: 10.1038/s41586-020-2600-6. Epub 2020 Jul 29.
4
Immunology of COVID-19: Current State of the Science.COVID-19 的免疫学：科学现状。
Immunity. 2020 Jun 16;52(6):910-941. doi: 10.1016/j.immuni.2020.05.002. Epub 2020 May 6.
5
Human neutralizing antibodies elicited by SARS-CoV-2 infection.SARS-CoV-2 感染诱导的人体中和抗体。
Nature. 2020 Aug;584(7819):115-119. doi: 10.1038/s41586-020-2380-z. Epub 2020 May 26.
6
Antibody responses to SARS-CoV-2 in patients with COVID-19.新型冠状病毒肺炎（COVID-19）患者的 SARS-CoV-2 抗体反应。
Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
7
The trinity of COVID-19: immunity, inflammation and intervention.COVID-19 的三位一体：免疫、炎症和干预。
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
8
Translating IL-6 biology into effective treatments.将 IL-6 生物学转化为有效治疗方法。
Nat Rev Rheumatol. 2020 Jun;16(6):335-345. doi: 10.1038/s41584-020-0419-z. Epub 2020 Apr 23.
9
Deployment of convalescent plasma for the prevention and treatment of COVID-19.恢复期血浆在 COVID-19 预防和治疗中的应用。
J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.
10
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.针对 SARS-CoV-2 和其他人类冠状病毒的中和抗体。
Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.